JP7736313B2 - αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用 - Google Patents

αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用

Info

Publication number
JP7736313B2
JP7736313B2 JP2022542038A JP2022542038A JP7736313B2 JP 7736313 B2 JP7736313 B2 JP 7736313B2 JP 2022542038 A JP2022542038 A JP 2022542038A JP 2022542038 A JP2022542038 A JP 2022542038A JP 7736313 B2 JP7736313 B2 JP 7736313B2
Authority
JP
Japan
Prior art keywords
formula
compound
2ohoa
dha
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022542038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518640A5 (enExample
JP2023518640A (ja
Inventor
ルイス，パブロ ビセンテ エスクリバ
カナレホ，マニュエル トーレス
シャウベット，ザビエル ブスケツ
カネーリャス，ビクトリア リャド
ガルシア，パウラ フェルナンデス
カスティーヨ，カタリナ アナ ロセヨ
バリオス，セバスティーヤ パレツ
ゴーベル，ロベルト ベテタ
ウレゴ，エミルセ カノ
ゴンザレス，ラウラ アルボナ
ロルカ，ラケル ロドリゲス
バウザ，フアン キャボット
ピザ，マルク ミリャーレス
Original Assignee
ウニバシタット デ レス イレス バレアース
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES202030070A external-priority patent/ES2846824B2/es
Priority claimed from ES202031155A external-priority patent/ES2911474B2/es
Application filed by ウニバシタット デ レス イレス バレアース filed Critical ウニバシタット デ レス イレス バレアース
Publication of JP2023518640A publication Critical patent/JP2023518640A/ja
Publication of JP2023518640A5 publication Critical patent/JP2023518640A5/ja
Application granted granted Critical
Publication of JP7736313B2 publication Critical patent/JP7736313B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022542038A 2020-01-29 2021-01-28 αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用 Active JP7736313B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
ESP202030070 2020-01-29
ES202030070A ES2846824B2 (es) 2020-01-29 2020-01-29 Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
EP20382145.9 2020-02-28
EP20382145 2020-02-28
ESP202031155 2020-11-17
ES202031155A ES2911474B2 (es) 2020-11-17 2020-11-17 Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
PCT/ES2021/070068 WO2021152201A2 (es) 2020-01-29 2021-01-28 Metabolitos de ácidos grasos alfa-hidroxilados, usos médicos de los mismos y uso como biomarcadores

Publications (3)

Publication Number Publication Date
JP2023518640A JP2023518640A (ja) 2023-05-08
JP2023518640A5 JP2023518640A5 (enExample) 2024-02-05
JP7736313B2 true JP7736313B2 (ja) 2025-09-09

Family

ID=77078835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542038A Active JP7736313B2 (ja) 2020-01-29 2021-01-28 αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用

Country Status (12)

Country Link
US (1) US20230097753A1 (enExample)
EP (1) EP4098649A4 (enExample)
JP (1) JP7736313B2 (enExample)
KR (1) KR20220132552A (enExample)
CN (1) CN115052852A (enExample)
AU (2) AU2021212330A1 (enExample)
BR (1) BR112022015172A2 (enExample)
CA (2) CA3233141A1 (enExample)
CL (1) CL2022001985A1 (enExample)
IL (1) IL295120A (enExample)
MX (1) MX2022009035A (enExample)
WO (1) WO2021152201A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
ES2982396A1 (es) * 2023-03-14 2024-10-15 Veritas Therapeutics S L 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520344A (ja) 2009-03-16 2012-09-06 リポファーマ セラピューティクス、エス．エル 多価不飽和脂肪酸ヒドロキシ誘導体及びその薬物としての使用
JP2012528793A (ja) 2009-05-29 2012-11-15 ニュー チャプター，インコーポレイテッド 脂質組成を調節するための組成物および方法
JP2014530806A (ja) 2011-10-07 2014-11-20 ウニベルシダッド・デ・レス・イレス・バレアルス 脂肪酸の２−ヒドロキシド誘導体のエナンチオマー

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195296B (de) * 1958-06-28 1965-06-24 Dr Gernot Grimmer Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der cis-9-Pentadecensaeure und der cis-9-Heptadecensaeure
DE1147221B (de) * 1958-06-28 1963-04-18 Dr Rer Nat Gernot Grimmer Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der Pentadecen- und Heptadecensaeuren
GB1156465A (en) * 1967-02-16 1969-06-25 Unilever Ltd Prostaglandins
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
DE102007055344A1 (de) * 2007-11-19 2009-05-20 K. D. Pharma Bexbach Gmbh Neue Verwendung von Omega-3-Fettsäure(n)
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
CN102276444B (zh) * 2011-05-04 2013-10-09 厦门大学 脂肪酸类化合物及其制备方法与应用
WO2014113584A1 (en) * 2013-01-16 2014-07-24 Rhode Island Hospital Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
US20150173410A1 (en) * 2013-12-19 2015-06-25 Change Cola, Inc. Beverage comprising omega fatty acid
JP2016222590A (ja) * 2015-05-29 2016-12-28 国立大学法人東京海洋大学 脂肪酸の同位体標識化合物の製造方法およびその方法により得られた脂肪酸の同位体標識化合物、ならびに診断薬
WO2019241728A1 (en) * 2018-06-15 2019-12-19 Youhealth Biotech, Limited Composition and methods for modulation of elovl2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012520344A (ja) 2009-03-16 2012-09-06 リポファーマ セラピューティクス、エス．エル 多価不飽和脂肪酸ヒドロキシ誘導体及びその薬物としての使用
JP2012528793A (ja) 2009-05-29 2012-11-15 ニュー チャプター，インコーポレイテッド 脂質組成を調節するための組成物および方法
JP2014530806A (ja) 2011-10-07 2014-11-20 ウニベルシダッド・デ・レス・イレス・バレアルス 脂肪酸の２−ヒドロキシド誘導体のエナンチオマー

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Larsen, L.N. et al.，Heneicosapentaenoate (21:5n-3): Its Incorporation into Lipids and Its Effects on Arachidonic Acid and Eicosanoid Synthesis，Lipids，1997年，32 (7)，707-714
Teres, Silvia et al.，2-Hydroxyoleate, a nontoxic membrane binding anticancer drug, induces glioma cell differentiation and autophagy，PANS，2012年，109 (22)，8489-8494

Also Published As

Publication number Publication date
AU2023248158B2 (en) 2025-11-27
IL295120A (en) 2022-09-01
AU2021212330A1 (en) 2022-09-22
EP4098649A4 (en) 2024-04-17
BR112022015172A2 (pt) 2022-10-11
AU2023248158A1 (en) 2023-11-02
CL2022001985A1 (es) 2023-02-03
WO2021152201A2 (es) 2021-08-05
CN115052852A (zh) 2022-09-13
WO2021152201A3 (es) 2021-09-23
MX2022009035A (es) 2022-08-11
KR20220132552A (ko) 2022-09-30
US20230097753A1 (en) 2023-03-30
CA3166307C (en) 2024-05-21
CA3233141A1 (en) 2021-08-05
CA3166307A1 (en) 2021-08-05
EP4098649A2 (en) 2022-12-07
JP2023518640A (ja) 2023-05-08

Similar Documents

Publication Publication Date Title
AU2023248158B2 (en) Alpha-Hydroxylated Fatty-Acid Metabolites, Medical Uses of Same and Use as Biomarkers
KR101833772B1 (ko) 고도불포화 지방산 유도체의 의약으로서 용도
Wen et al. DHA-PC and DHA-PS improved Aβ1–40 induced cognitive deficiency uncoupled with an increase in brain DHA in rats
JP6506206B2 (ja) Ｐｕｆａ誘導体による酸化ストレス障害の緩和
JP7025212B2 (ja) 炎症性、変性及び神経変性疾患の治療のための化合物、組成物及び方法
US20110280852A1 (en) Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
CN1440240A (zh) 用于预防和/或治疗血管疾病的制剂
US9968629B2 (en) Product and method for supporting uridine homeostasis
Gregoire et al. Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys
EP4554929A1 (en) Preparation of stable psilocin salts, esters and conjugates and uses thereof
RU2841595C1 (ru) Метаболиты альфа-гидроксилированных жирных кислот, их медицинские применения и применение в качестве биомаркеров
WO2010007788A1 (ja) グリチルレチン酸誘導体及びその利用
HK40081413A (en) Alpha-hydroxylated fatty-acid metabolites, medical uses of same and use as biomarkers
EP3471828A1 (en) Compositions and methods useful for treating diseases characterized by insufficient pantothenate kinase activity
CN107428671A (zh) 用于合成羟基‑三甘油酯的方法及其用于预防和治疗疾病的用途
ES2846824B2 (es) Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
ES2911474B2 (es) Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
JP2024523589A (ja) アンジオテンシン及びその類似体の投与によるシナプス形成の誘導方法
WO2022186170A1 (ja) 脳血管障害を予防または治療するための組成物
KR20250027638A (ko) 니코틴산 또는 그 유도체 및 지방산 또는 그 유도체를 포함하는 조합물 및 조성물
JP2024501636A (ja) Ｐｋｃ活性化剤を使用した筋萎縮性側索硬化症の治療

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220812

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221028

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20220906

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250818

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250821

R150 Certificate of patent or registration of utility model

Ref document number: 7736313

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150